Making Better Tomorrow, Bukwang Pharmaceutical. Bukwang R&D
NEWS

Bukwang registered a composition patent for SOL-804 in the U.S.

[November 11, 2021]

Bukwang Pharmaceutical (“Bukwang”) announced that its subsidiary, Dyna Therapeutics (“Dyna”) registered a composition patent for anti-cancer drug ‘SOL-804’ (Title: Solid oral formulation of lipophilic compound) to the U.S. The patent is also approved in Japan, Eurasia, Europe, Australia, Mexico, and Singapore.The process of applying for patents is ongoing in Brazil, Canada, China, Hongkong, Israel, India, Korea, Newzealand, and the republic of South Africa. Phase 1 clinical study of SOL-804 is going to be conducted soon in Seoul National Univ.hospital...

R&D

Bukwang registered a composition patent for SOL-804 in the U.S.

[November 11, 2021]

Bukwang Pharmaceutical (“Bukwang”) announced that its subsidiary, Dyna Therapeutics (“Dyna”) registered a composition patent for anti-cancer...

COMPANY

Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years. Since Bukwang was listed in the Korea Stock Exchange...

Conterapharma
콘테라로고.jpg

Unlocking science for treating neurological disorders

   

Discover Bukwang

PRODUCTS
main_cg.jpg
|    ​Korean    |